TrialJournal of hematology & oncology2020

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.

Runxia Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.